Risankizumab-rzaa
Category: Skin CareRisankizumab-rzaa Overview
Risankizumab, sold under the brand name Skyrizi, is a humanized monoclonal antibody targeting interleukin 23A (IL-23A).[5] Risankizumab is part of a collaboration between Boehringer Ingelheim and AbbVie. Risankizumab has been approved in the European Union,[4] the United States,[3][6] Canada, and Japan for treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.[citation needed&a...
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Risankizumab
Recent Risankizumab-rzaa Forums:
Be the first to start a discussion about this drug.Possible Dosages for this and Related Drugs:
Risankizumab-rzaa
- Injection: 75mg/0.83ml
Other drugs which contain Risankizumab-rzaa or a similar ingredient: (1 result)
- SKYRIZI Risankizumab-rzaa